ReviewmicroLife2022
Lipid A heterogeneity and its role in the host interactions with pathogenic and commensal bacteria.
Review in microLife, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 20 citations in OpenAlex.
- Maternal obesity alters human milk oligosaccharides content and correlates with early acquisition of late colonizers in the neonatal gut microbiome.Gut microbes · 2026Article
- Design, synthesis, and antibacterial activity study of pyrroloquinazoline diamine derivatives.Journal of enzyme inhibition and medicinal chemistry · 2026Article
- Bacterial cell envelope components of gut commensals: effects in host-microbe interaction.Annals of medicine · 2026Review
- Kinetics and mechanisms in lipopolysaccharide-induced neuroinflammation: a framework for phytochemicals screening.Molecular biology reports · 2026Review
- Beyond Infection: Mitochondrial Reprogramming and Immunometabolic Adaptation inDiseases (Basel, Switzerland) · 2026Article
- Immunogenicity of an Oil-in-Water Emulsion ContainingVaccines · 2026Article
- Smoking-associated modulation of gut microbiota shapes response to immune checkpoint inhibitors in non-small cell lung cancer.Cancer immunology, immunotherapy : CII · 2026Article
- Stepwise assembly of virulence-associated traits in the intracellular pathogenbioRxiv : the preprint server for biology · 2026Article
- The role of gut microbiome disruption in the development of metabolic dysfunction-associated kidney disease.Acta biochimica Polonica · 2026Review
- Structural and Immunological Insights into the Lipooligosaccharide of the Marine BacteriumMarine drugs · 2025Article
- A critical role forProceedings of the National Academy of Sciences of the United States of America · 2025Article
- 2‑Aminoimidazole-benzimidazole Conjugates Potentiate the Gram-Positive Selective Antibiotic Clarithromycin againstACS medicinal chemistry letters · 2025Article
- Discrimination of Klebsiella pneumoniae and Klebsiella quasipneumoniae by MALDI-TOF Mass Spectrometry Coupled With Machine Learning.MicrobiologyOpen · 2025Article
- Milestones in the development ofJournal of bacteriology · 2025Review
- Unraveling the gut microbiota's role in obesity: key metabolites, microbial species, and therapeutic insights.Journal of bacteriology · 2025Review
- Research advancements in nanoparticles and cell-based drug delivery systems for the targeted killing of cancer cells.Oncology research · 2025Review
- Synthesis and biological evaluation of lipid A derived from commensalOrganic & biomolecular chemistry · 2024Article
- Article
- Diversity, Complexity, and Specificity of Bacterial Lipopolysaccharide (LPS) Structures Impacting Their Detection and Quantification.International journal of molecular sciences · 2024Article
- Defense mechanisms ofFrontiers in antibiotics · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lipopolysaccharide (LPS) is for most but not all Gram-negative bacteria an essential component of the outer leaflet of the outer membrane. LPS contributes to the integrity of the outer membrane, which acts as an effective permeability barrier to antimicrobial agents and protects against complement-mediated lysis. In commensal and pathogenic bacteria LPS interacts with pattern recognition receptors (e.g LBP, CD14, TLRs) of the innate immune system and thereby plays an important role in determining the immune response of the host. LPS molecules consist of a membrane-anchoring lipid A moiety and the surface-exposed core oligosaccharide and O-antigen polysaccharide. While the basic lipid A structure is conserved among different bacterial species, there is still a huge variation in its details, such as the number, position and chain length of the fatty acids and the decoration of the glucosamine disaccharide with phosphate, phosphoethanolamine or amino sugars. New evidence has emerged over the last few decades on how this lipid A heterogeneity confers distinct benefits to some bacteria because it allows them to modulate host responses in response to changing host environmental factors. Here we give an overview of what is known about the functional consequences of this lipid A structural heterogeneity. In addition, we also summarize new approaches for lipid A extraction, purification and analysis which have enabled analysis of its heterogeneity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.